Evolus Achieves Q4 2025 Profitability, Projects Sustainable Annual Profitability in 2026, and Raises Long-Term Outlook
EOLS is trading near its 52-week low of $5.61 (0.4% below the low).
Summary
Evolus announced preliminary Q4 and full-year 2025 net revenues, reaffirming positive non-GAAP operating income for Q4 2025 and projecting sustainable annual profitability starting in 2026, alongside strong 2026 guidance and an updated long-term financial outlook.
Key Events · Earnings and Guidance · EOLS
-
Achieved Q4 2025 Profitability
The company reaffirmed positive non-GAAP operating income of $5 million to $7 million for the fourth quarter of 2025.
-
Strong 2025 Revenue Growth
Preliminary unaudited net revenue for full-year 2025 is expected to be between $295.5 million and $297.5 million, representing 11% to 12% growth over the prior year.
-
Positive 2026 Guidance
Total net revenues for 2026 are projected to be between $327 million and $337 million, an 11% to 13% increase, with sustainable annual profitability expected to begin in 2026.
-
Updated Long-Term Outlook
The 2028 long-term financial outlook was updated to reflect total net revenue of $450 million to $500 million and non-GAAP operating income margins of 13% to 15%.
Analysis · EOLS · Life Sciences
Evolus's preliminary financial results indicate a significant milestone with the achievement of positive non-GAAP operating income in Q4 2025, a key indicator of operational efficiency and financial health. The projection of sustainable annual profitability beginning in 2026, coupled with double-digit revenue growth guidance for 2026 and an increased long-term revenue outlook for 2028, suggests a strong growth trajectory and improved financial discipline. This news, especially while the stock is trading near its 52-week low, could signal a potential turning point for investor sentiment, highlighting the company's ability to gain market share and diversify its product portfolio.
At the time of this filing, EOLS was trading at $5.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $372.1M. The 52-week trading range was $5.61 to $17.12. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.